BOULDER, Colo.--Xenometrix, a biotechnology company here that uses its proprietary gene profiling technology to help the pharmaceutical industry optimize drug leads, has released financial results for the quarter ended September 30 that a show a slight gain in revenue over the same period a year ago, but a loss in net income and net per share. The losses are in part the result of a loss of grant money, greater R&D expenditures, new interest expenses, and an extraordinary gain recorded in the comparable period in 1996.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.